J INTS BIO, Phase 1/2 study of ‘JIN-A02’, a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Posted on by

SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ — J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI “JIN-A02” for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.